Drug information provided by: Merative, Micromedex®
Polatuzumab vedotin-piiq injection is used together with other cancer medicines (eg, bendamustine, rituximab) to treat diffuse large B-cell lymphoma (DLBCL) that has come back a second or later time or after at least 2 other medicines did not work well. Lymphoma is a type of cancer where the body makes abnormal white blood cells.
Polatuzumab vedotin-piiq injection is also used together with other medicines (eg, rituximab, cyclophosphamide, doxorubicin, and prednisone) to treat previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL), and who have an International Prognostic Index score of 2 or more.
Polatuzumab vedotin-piiq interferes with the growth of cancer cells, which are then destroyed by the body.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.